Shots:
- NICE has issued a final appraisal determination (FAD) which recommends UCB’s bimekizumab as a treatment option for adults with severe PsO
- The recommendation is based on four P-III studies i.e BE VIVID, BE RADIANT (P- IIIb), BE READY & BE SURE that demonstrated the superior efficacy and safety of bimekizumab in adults with PsO against PBO, ustekinumab, secukinumab and adalimumab
- The company expects MHRA’s decision for approval in the next few mos. if approved, NICE will give final technology appraisal guidance & bimekizumab will be available in England and Wales. The therapy is also under review in the EU & US
Click here to to read full press release/ article | Ref: NICE | Image: NICE
The post UCB’s Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis first appeared on PharmaShots.
